Published Date: 24 Jun 2024
Phase II study found brigatinib exceeded historical control by shrinking 10% of targeted tumors
Read Full NewsNew phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.
Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.
1.
Genetics and therapy type determine second cancer risk after childhood treatment, study finds
2.
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer
3.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
4.
Alternative Medicine for Breast Cancer: Study Raises Concern
5.
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types
1.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
2.
Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma
3.
Hematopoietic Resilience and Future Clinical Performance: Mechanisms, Clinical Implications, and Emerging Perspectives
4.
Automated Microvascular Suturing for Hematologic Patients: A Comprehensive Review
5.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Clinical Insights in Hematology
3.
How Hematologists Evaluate Persistent Blood Abnormalities
4.
Hematologic Fatigue and Work Function: Clinical Implications, Pathophysiology, and Management
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation